2026-09-10T17:24:20+00:00 2025-12-31 580692043 MAULDIN & JENKINS LLC 200 GALLERIA PARKWAY SUITE 1700 ATLANTA GA 30339 990 2025-01-01 822120760 ODYLIA THERAPEUTICS INC ODYL 4044802994 830 GLENWOOD AVE SE 510-32 ATLANTA GA 30316 ASHLEY WINSLOW CEO/CSO 4044802994 2026-09-10 true MELISSA SEWARD P02145103 7709558600 2026-09-10 2025 ASHLEY WINSLOW 830 GLENWOOD AVE SE 510-32 ATLANTA GA 30316 2090096 false X ODYLIA.ORG X 2017 DE ODYLIA THERAPEUTICS IS A NONPROFIT BIOTECH DEVELOPING AND ADVANCING THERAPEUTICS FOR PEOPLE WITH RARE DISEASES, CHANGING THE WAY TREATMENTS ARE BROUGHT FROM THE LAB TO THE PATIENTS WHO NEED THEM. 8 8 4 8 0 291256 898455 144417 609083 46374 15826 0 0 482047 1523364 0 0 0 0 556221 611716 0 0 102780 143184 795253 699405 1406969 -217358 116395 1594795 1741781 907239 921012 687556 820769 ODYLIA UTILIZES A UNIQUE, NON-PROFIT MODEL TO DEVELOP AND ADVANCE THERAPEUTICS FOR PEOPLE WITH RARE DISEASES, CHANGING THE WAY TREATMENTS ARE BROUGHT FROM THE LAB TO THE CLINIC. false false 1197948 609083 ODYLIA'S TWO PRIMARY INITIATIVES ARE THE ODYLIA PIPELINE AND BRYDGE SOLUTIONS. THE PIPELINE INCLUDES THE RPGRIP1, USH1C, AND NPHP1 GENE THERAPY PROGRAMS. SIGNIFICANT ACCOMPLISHMENTS INCLUDED A SUCCESSFUL FDA PRE-IND MEETING AND PRECLINICAL DEVELOPMENT ACTIVITIES FOR THE RPGRIP1 PROGRAM, CLINICAL CANDIDATE SELECTION AND DELIVERY OPTIMIZATION FOR THE USH1C PROGRAM, AND INITIAL VECTOR DESIGN AND TESTING FOR THE NPHP1 PROGRAM. BRYDGE SOLUTIONS ACCELERATES THE DEVELOPMENT OF TREATMENTS FOR RARE DISEASES THROUGH STRATEGIC PARTNERSHIPS WITH PATIENT ADVOCACY ORGANIZATIONS, DISEASE FOUNDATIONS, AND RARE DISEASE FAMILIES. IN 2025, THE PROGRAM ESTABLISHED FIVE NEW PARTNERSHIPS WITH SAVE SIGHT NOW, MED13L FOUNDATION, UPSTREAM GENES, DLG4 SHINE SYNDROME FOUNDATION, AND PBD PROJECT. 1197948 true true false false false false false false false false false false false false false true true false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false false false false true 3 0 true 4 true false false false false false false false false false false false false X 8 8 false false false false true true false true true false false false true true true true true true true false false false MA X X THE ORGANIZATION 4044802994 830 GLENWOOD AVE SE 510-323 ATLANTA GA 30316 GREG ROBINSON VICE CHAIR 1.0 X X 0 0 0 SCOTT DORFMAN BOARD CHAIR 3.0 X X 0 0 0 BRIAN FENTON BOARD MEMBER 1.0 X 0 0 0 ELIZABETH ATTIAS BOARD MEMBER 1.0 X 0 0 0 JOY CAVAGNARO BOARD MEMBER 1.0 X 0 0 0 KHANDAN BARADARAN BOARD MEMBER 1.0 X 0 0 0 MATTHEW PLETCHER BOARD MEMBER 1.0 X 0 0 0 WENDY ERLER BOARD MEMBER 1.0 X 0 0 0 ASHLEY WINSLOW CEO/CSO 40.0 X 212578 0 17848 JENNIFER KLEIN MGR. OF OPERATIONS & PROG. MGMT. 40.0 X 118296 0 318 KATHRYN POST PHD DIRECTOR, BRYDGE SOLUTIONS 40.0 X 105324 0 269 436198 0 18435 3 false true false VIRSCIO INC 5 SCIENCE PARK NEW HAVEN CT 06511 MEDICAL RESEARCH SERVICES 336974 ANDELYN BIOSCIENCES 1180 ARTHUR E ADAMS DR COLUMBUA OH 43221 MEDICAL GENE THERAPY MANUF. 317780 2 898455 898455 SERVICE FEE REVENUE 900099 609083 609083 0 0 0 0 609083 65208 65208 0 0 517350 566732 -49382 0 -49382 -49382 0 0 0 0 0 0 1523364 609083 0 15826 X 0 0 212578 184943 25509 2126 320216 219983 35608 64625 41763 29964 5595 6204 37159 28337 4052 4770 22439 22439 738105 726669 1827 9609 18290 5692 452 12146 6663 441 6040 182 5649 2752 2897 3639 1919 1514 206 468 453 15 0 0 0 0 1406969 1197948 106241 102780 236414 208757 673208 420329 10154 63188 0 0 0 0 0 766 0 0 0 0 675019 1047728 0 0 0 1013 1594795 1741781 55532 170150 851707 750862 0 0 0 0 907239 921012 X 687556 820769 687556 820769 1594795 1741781 116395 16818 0 X X false true true false X 233084 976484 289283 291256 898455 2688562 0 0 0 0 233084 976484 289283 291256 898455 2688562 843330 1845232 10396 14556 40401 46374 65208 176935 0 0 0 0 0 0 0 0 2865497 1201950 0.64395 0.47318 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 X 1651876 16818 111694 0 128512 1523364 0 0 1523364 1518663 111694 0 111694 1406969 0 0 1406969 SCHEDULE D, PART X, LINE 2 FIN 48 (ASC 740) FOOTNOTE THE ORGANIZATION QUALIFIES AS A TAX-EXEMPT ORGANIZATION AS DESCRIBED IN INTERNAL REVENUE CODE SECTION 501(C)(3) AND HAS BEEN CLASSIFIED BY THE INTERNAL REVENUE SERVICE AS A PUBLICLY SUPPORTED ORGANIZATION AND NOT AS A PRIVATE ORGANIZATION. HOWEVER, INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO THE ORGANIZATION'S TAX-EXEMPT PURPOSE IS SUBJECT TO TAXATION AS UNRELATED BUSINESS INCOME. THE ORGANIZATION FOLLOWS THE STATUTORY REQUIREMENTS FOR ITS INCOME TAX ACCOUNTING AND GENERALLY AVOIDS RISKS ASSOCIATED WITH POTENTIALLY PROBLEMATIC TAX POSITIONS THAT MAY BE CHALLENGED UPON EXAMINATION. MANAGEMENT BELIEVES ANY LIABILITY RESULTING FROM TAXING AUTHORITIES IMPOSING ADDITIONAL INCOME TAXES FROM ACTIVITIES DEEMED TO BE UNRELATED TO THE ORGANIZATION'S TAX-EXEMPT STATUS WOULD NOT HAVE A MATERIAL EFFECT ON THE ORGANIZATION'S FINANCIAL STATEMENTS. THE ORGANIZATION HAS NO UNCERTAIN TAX POSITIONS UNDER FIN 48 (ASC 740). X X false false false false false false false false false ASHLEY WINSLOW CEO/CSO 212578 0 0 0 0 0 0 0 17848 0 230426 0 0 0 FORM 990, PART I, LINE 1 ODYLIA THERAPEUTICS UTILIZES A UNIQUE NONPROFIT MODEL TO ACCELERATE THE RESEARCH AND DEVELOPMENT OF SAFE AND EFFECTIVE TREATMENTS FOR RARE AND ULTRA-RARE DISEASES. ODYLIA'S ACTIVITIES INCLUDE CONDUCTING AND SUPPORTING RESEARCH AND DEVELOPMENT OF THERAPIES FOR RARE AND ULTRA-RARE DISEASE PATIENTS; DEVELOPING AND EVALUATING METHODOLOGIES AND BEST PRACTICES TO IMPROVE THE EFFICIENCY AND EFFECTIVENESS OF THERAPEUTIC DEVELOPMENT, INCLUDING THE CONDUCT AND OVERSIGHT OF CLINICAL TRIALS; COMPILING AND DISSEMINATING SCIENTIFIC INFORMATION AND LITERATURE TO ADVANCE RESEARCH AND ATTRACT RESOURCES TO THE DEVELOPMENT OF TREATMENTS; AND COLLABORATING WITH RESEARCHERS, CLINICIANS, PATIENT COMMUNITIES, ADVOCACY ORGANIZATIONS, AND OTHER STAKEHOLDERS TO ADVANCE PROMISING THERAPEUTIC PROGRAMS. THROUGH THESE ACTIVITIES, ODYLIA SEEKS TO REDUCE BARRIERS AND COSTS ASSOCIATED WITH DEVELOPING TREATMENTS AND HELP MOVE PROMISING THERAPIES FROM RESEARCH TOWARD CLINICAL APPLICATION. FORM 990, PART VI, LINE 6 CLASSES OF MEMBERS OR STOCKHOLDERS THE ORGANIZATION HAS TWO STATUTORY MEMBERS, THE MASSACHUSETTS EYE AND EAR INFIRMARY AND USHER 2020 FOUNDATION, INC. FORM 990, PART VI, LINE 7A MEMBERS OR STOCKHOLDERS ELECTING MEMBERS OF GOVERNING BODY THE ORGANIZATION'S MEMBERS CAN ELECT OR APPOINT 2 DIRECTORS OF THE GOVERNING BODY. FORM 990, PART VI, LINE 11B REVIEW OF FORM 990 BY GOVERNING BODY THE BOARD OF DIRECTORS ARE PROVIDED WITH FORM 990 FOR THE OPPORTUNITY TO PROVIDE COMMENTS AND QUESTIONS, WITHIN TWO WEEKS OF DOCUMENT PROVISION, TO ENSURE THERE IS TIME FOR DISCUSSION BEFORE SUBMISSION. FORM 990, PART VI, LINE 12C CONFLICT OF INTEREST POLICY BOARD MEMBERS AND STAFF ARE ASKED TO DISCLOSE CONFLICT OF INTEREST THROUGH A FORM THAT IS FILLED OUT. ANY CHANGES IN CONFLICT OF INTERESTS ARE ASKED TO BE UPDATED WHEN CHANGES OCCUR, AND AT LEAST ANNUALLY. FORM 990, PART VI, LINE 15A PROCESS TO ESTABLISH COMPENSATION OF TOP MANAGEMENT OFFICIAL DISCUSSED WITH INDUSTRY EXPERTS AND INDEPENDENT BOARD MEMBERS TO DETERMINE COMPENSATION. FORM 990, PART VI, LINE 19 REQUIRED DOCUMENTS AVAILABLE TO THE PUBLIC DOCUMENTS ARE AVAILABLE UPON REQUEST AND THROUGH THE ORGANIZATION'S WEBSITE. FORM 990, PART IX, LINE 11G OTHER FEES HR ADMINISTRATION - TOTAL EXPENSE: 13730, PROGRAM SERVICE EXPENSE: 9794, MANAGEMENT AND GENERAL EXPENSES: 1827, FUNDRAISING EXPENSES: 2109; PROFESSIONAL SERVICES - TOTAL EXPENSE: 16238, PROGRAM SERVICE EXPENSE: 8738, MANAGEMENT AND GENERAL EXPENSES: , FUNDRAISING EXPENSES: 7500; MEDICAL CONTRACT SERVICES - TOTAL EXPENSE: 708137, PROGRAM SERVICE EXPENSE: 708137, MANAGEMENT AND GENERAL EXPENSES: , FUNDRAISING EXPENSES: ; FORM 990, PART XII, LINE 2C CHANGE OF OVERSIGHT PROCESS OR SELECTION PROCESS THE OVERSIGHT PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.